AB
CRL icon

Amalgamated Bank’s Charles River Laboratories CRL Stock Holding History

Amalgamated Bank’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.93M Sell
8,487
-460
-5% -$81.9K 0.01% 855
2026
Q1 		$1.54M Sell
8,947
-750
-8% -$139K 0.01% 910
2025
Q4 		$1.93M Buy
9,697
+384
+4% +$69.7K 0.01% 834
2025
Q3 		$1.46M Sell
9,313
-149
-2% -$23.7K 0.01% 929
2025
Q2 		$1.44M Sell
9,462
-430
-4% -$57.3K 0.01% 908
2025
Q1 		$1.49M Buy
9,892
+24
+0.2% +$4.02K 0.01% 893
2024
Q4 		$1.82M Sell
9,868
-253
-2% -$48.7K 0.02% 830
2024
Q3 		$1.99M Sell
10,121
-2,915
-22% -$606K 0.02% 819
2024
Q2 		$2.69M Buy
13,036
+2,323
+22% +$526K 0.02% 726
2024
Q1 		$2.9M Sell
10,713
-5,129
-32% -$1.22M 0.02% 717
2023
Q4 		$3.75M Sell
15,842
-1,433
-8% -$282K 0.03% 631
2023
Q3 		$3.39M Buy
17,275
+1,615
+10% +$332K 0.03% 629
2023
Q2 		$3.29M Sell
15,660
-2,843
-15% -$566K 0.03% 655
2023
Q1 		$3.73M Sell
18,503
-964
-5% -$218K 0.03% 584
2022
Q4 		$4.24M Buy
19,467
+338
+2% +$73.8K 0.04% 568
2022
Q3 		$3.77M Buy
19,129
+262
+1% +$56.6K 0.04% 535
2022
Q2 		$4.04M Sell
18,867
-187
-1% -$45.7K 0.04% 525
2022
Q1 		$5.41M Buy
19,054
+271
+1% +$83.6K 0.04% 433
2021
Q4 		$7.08M Sell
18,783
-219
-1% -$85.1K 0.05% 344
2021
Q3 		$7.84M Sell
19,002
-583
-3% -$242K 0.07% 274
2021
Q2 		$7.25M Buy
19,585
+10,483
+115% +$3.5M 0.06% 336
2021
Q1 		$2.64M Sell
9,102
-782
-8% -$217K 0.1% 162
2020
Q4 		$2.47M Buy
9,884
+39
+0.4% +$9.29K 0.09% 177
2020
Q3 		$2.23M Sell
9,845
-253
-3% -$52.5K 0.1% 167
2020
Q2 		$1.76M Sell
10,098
-2,955
-23% -$472K 0.08% 205
2020
Q1 		$1.65M Sell
13,053
-264
-2% -$39.6K 0.04% 431
2019
Q4 		$2.03M Buy
13,317
+825
+7% +$114K 0.04% 505
2019
Q3 		$1.65M Buy
12,492
+1,392
+13% +$187K 0.03% 535
2019
Q2 		$1.57M Buy
11,100
+385
+4% +$52.2K 0.04% 543
2019
Q1 		$1.56M Buy
10,715
+161
+2% +$21.2K 0.04% 517
2018
Q4 		$1.2M Buy
10,554
+2,901
+38% +$363K 0.03% 569
2018
Q3 		$1.03M Sell
7,653
-3,284
-30% -$405K 0.03% 676
2018
Q2 		$1.23M Buy
10,937
+390
+4% +$42.2K 0.03% 650
2018
Q1 		$1.13M Buy
10,547
+642
+6% +$69.2K 0.03% 653
2017
Q4 		$1.08M Buy
9,905
+514
+5% +$55.9K 0.03% 674
2017
Q3 		$1.01M Sell
9,391
-58
-0.6% -$5.96K 0.03% 647
2017
Q2 		$956K Buy
9,449
+1,933
+26% +$178K 0.03% 675
2017
Q1 		$676K Sell
7,516
-1,504
-17% -$128K 0.03% 658
2016
Q4 		$687K Buy
9,020
+868
+11% +$65.9K 0.03% 678
2016
Q3 		$679K Sell
8,152
-1
-0% -$84 0.04% 574
2016
Q2 		$679K Buy
8,153
+2,337
+40% +$192K 0.04% 579
2016
Q1 		$442K Buy
5,816
+438
+8% +$32.4K 0.04% 604
2015
Q4 		$432K Sell
5,378
-370
-6% -$26.7K 0.05% 525
2015
Q3 		$365K Buy
5,748
+79
+1% +$5.67K 0.04% 739
2015
Q2 		$399K Buy
5,669
+2,220
+64% +$164K 0.04% 731
2015
Q1 		$273K Buy
3,449
+190
+6% +$14K 0.03% 719
2014
Q4 		$207K Buy
+3,259
New +$204K 0.03% 785

Other funds holding CRL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CB
Cooke & Bieler Philadelphia, Pennsylvania $8.65B AUM 9.66% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
VBA
Van Berkom & Associates Montreal, Quebec, Canada $3.1B AUM 12.88% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return

Amalgamated Bank's CRL Position: Q2 2026 in Review

Amalgamated Bank reduced its Charles River Laboratories (CRL) stake by 5.1% in Q2 2026, selling an estimated $81.9K and leaving 8,487 shares worth $1.93M. The position accounts for 0.01% of the portfolio, ranked #855.

Amalgamated Bank first reported a position in CRL in Q4 2014 and has held it in 47 quarters since. The position peaked at $7.84M in Q3 2021. 287 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • Amalgamated Bank held 8,487 shares of Charles River Laboratories worth $1.93M as of Q2 2026.
  • Amalgamated Bank sold 460 Charles River Laboratories shares in Q2 2026, an estimated $81.9K.
  • Charles River Laboratories made up 0.01% of Amalgamated Bank's portfolio in Q2 2026, its #855 holding.
  • Amalgamated Bank first reported a position in Charles River Laboratories in Q4 2014 and has held it in 47 quarters since.
  • Amalgamated Bank's Charles River Laboratories position peaked at $7.84M in Q3 2021.
  • 287 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Amalgamated Bank's 13F filing for Q2 2026, filed 23 Jul 2026.